Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Gene-expression quantification methods

Published byKatherine Summers Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Gene-expression quantification methods"— Presentation transcript:

1 Figure 1 Gene-expression quantification methods
Figure 1 | Gene-expression quantification methods. Several multigene predictor platforms are currently in use, and these platforms involve various quantification methods including: a | reverse transcriptase-PCR, as used for quantification in the Oncotype DX, EndoPredict, and Breast Cancer Index assays. b | Nanostring technology, as used for quantification in the Prosigna assay; and c | DNA-microarray technology, as used for quantification in the MammaPrint assay. Kwa, M. et al. (2017) Clinical utility of gene-expression signatures in early stage breast cancer Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 1 Gene-expression quantification methods"

Similar presentations

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.
Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Figure 1 The heterogenous landscape of triple-negative breast cancer

Figure 1 The heterogenous landscape of triple-negative breast cancer
Reproduced with permission from Cronin M et al

Reproduced with permission from Cronin M et al
Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma

Similar presentations

Ads by Google